tetano
Editor, Senior Moderator
Expert Rev Neurother
. 2024 Dec 23:1-17.
doi: 10.1080/14737175.2024.2440543. Online ahead of print. Tackling persistent neurological symptoms in patients following acute COVID-19 infection: an update of the literature
Eder Cáceres[SUP] 1 2 3 [/SUP], Afshin A Divani[SUP] 4 [/SUP], Andre Emilio Viñan-Garces[SUP] 3 [/SUP], Juan Olivella-Gomez[SUP] 3 [/SUP], Alejandro Quintero-Altare[SUP] 3 [/SUP], Sebastián Pérez[SUP] 3 [/SUP], Luis F Reyes[SUP] 1 5 [/SUP], Nicholas Sasso[SUP] 6 [/SUP], Jose Biller[SUP] 6 [/SUP]
Affiliations
Introduction: The COVID-19 pandemic has taught myriad lessons and left several questions we are yet to comprehend. Initially, the scientific community was concerned with the management of acute disease and immunization. Once the peak of the pandemic receded, it became clear that a proportion of patients were far from fully recovered. Researchers started to recognize those persisting symptoms as a new entity termed 'Long COVID,' where neurological symptoms are evident and have a major impact on quality of life.
Areas covered: The main purpose of this narrative review is to analyze and synthesize the current literature regarding Long COVID, its relation to the nervous system, and to explore the evidence on treatments for persistent neurological symptoms. The most common reported and observed neurologic manifestations include fatigue, cognitive impairment, pain, polyneuropathy, and neuropsychiatric disorders. A variety of pharmacologic and non-pharmacologic therapies have been evaluated and yielded mixed results. Many of them focused on immunomodulation and none currently have U.S. FDA approval.
Expert opinion: Challenges remain in terms of clinical characterization and prognosis of Long COVID, besides understanding its pathophysiology. Standardization of biomarkers and diagnostic criteria will allow the use of common nomenclature and data elements in the design of future clinical studies.
Keywords: COVID-19; Long COVID; SARS-CoV-2; coronavirus; cytokine storm; neurocovid; neuropsychiatric symptoms.
. 2024 Dec 23:1-17.
doi: 10.1080/14737175.2024.2440543. Online ahead of print. Tackling persistent neurological symptoms in patients following acute COVID-19 infection: an update of the literature
Eder Cáceres[SUP] 1 2 3 [/SUP], Afshin A Divani[SUP] 4 [/SUP], Andre Emilio Viñan-Garces[SUP] 3 [/SUP], Juan Olivella-Gomez[SUP] 3 [/SUP], Alejandro Quintero-Altare[SUP] 3 [/SUP], Sebastián Pérez[SUP] 3 [/SUP], Luis F Reyes[SUP] 1 5 [/SUP], Nicholas Sasso[SUP] 6 [/SUP], Jose Biller[SUP] 6 [/SUP]
Affiliations
- PMID: 39715694
- DOI: 10.1080/14737175.2024.2440543
Introduction: The COVID-19 pandemic has taught myriad lessons and left several questions we are yet to comprehend. Initially, the scientific community was concerned with the management of acute disease and immunization. Once the peak of the pandemic receded, it became clear that a proportion of patients were far from fully recovered. Researchers started to recognize those persisting symptoms as a new entity termed 'Long COVID,' where neurological symptoms are evident and have a major impact on quality of life.
Areas covered: The main purpose of this narrative review is to analyze and synthesize the current literature regarding Long COVID, its relation to the nervous system, and to explore the evidence on treatments for persistent neurological symptoms. The most common reported and observed neurologic manifestations include fatigue, cognitive impairment, pain, polyneuropathy, and neuropsychiatric disorders. A variety of pharmacologic and non-pharmacologic therapies have been evaluated and yielded mixed results. Many of them focused on immunomodulation and none currently have U.S. FDA approval.
Expert opinion: Challenges remain in terms of clinical characterization and prognosis of Long COVID, besides understanding its pathophysiology. Standardization of biomarkers and diagnostic criteria will allow the use of common nomenclature and data elements in the design of future clinical studies.
Keywords: COVID-19; Long COVID; SARS-CoV-2; coronavirus; cytokine storm; neurocovid; neuropsychiatric symptoms.